Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

104.97 +1.05 (+1.01%)

Streaming Delayed Price Updated: 1:17 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...

Via MarketMinute

1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now ↗

March 19, 2026

Don't give up on this leading dividend payer yet.

Via The Motley Fool

1 Mid-Cap Stock to Consider Right Now and 2 Facing Headwinds

March 17, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum ↗

March 04, 2026

Via Chartmill

Hedge Fund Beryl Capital Initiated a Position in CSG Systems Worth Over $54 Million. Is the Stock a Buy? ↗

March 11, 2026

CSG Systems International delivers SaaS-based billing and customer engagement solutions to telecom and enterprise clients worldwide.

Via The Motley Fool

Macroeconomic Headwinds and Shifting Demand Force Healthcare Giants to Trim 2026 Outlooks

March 09, 2026

As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Cash-Producing Stocks We Approach with Caution

March 05, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"

March 04, 2026

As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time ↗

February 25, 2026

Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.

Via The Motley Fool

Topics Cannabis Initial Public Offering

Medtronic Hits 10-Quarter High: PFA Dominance and Robotic Surges Signal a New Era for MedTech

February 23, 2026

In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape

February 19, 2026

On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire...

Via MarketMinute

February 18, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

Topics Economy

3 Overrated Stocks That Concern Us

February 15, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Via StockStory

Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever ↗

February 12, 2026

Abbott is the name behind many well-known products.

Via The Motley Fool

1 Momentum Stock with Exciting Potential and 2 Facing Headwinds

February 08, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?

February 08, 2026

What a time it’s been for Exact Sciences. In the past six months alone, the company’s stock price has increased by a massive 152%, reaching $103.18 per share. This was partly due to its solid quarterly...

Via StockStory

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...

Via MarketMinute

Topics Artificial Intelligence Economy

1 Growth Stock to Stash and 2 We Avoid

February 05, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Topics Climate Change

The Best Dividend King to Buy With $150 ↗

February 02, 2026

The stock is near its 52-week low.

Via The Motley Fool

Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race

February 02, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The...

Via MarketMinute

Topics Artificial Intelligence

3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗

January 26, 2026

Investors' reaction to this Dividend King's Q4 revenue miss was overdone.

Via The Motley Fool

Topics Earnings

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Via MarketMinute

Topics Economy

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Via MarketMinute

Topics Earnings Economy

$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation

January 19, 2026

The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A

January 14, 2026

As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial...

Via MarketMinute

Topics Artificial Intelligence

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

Via MarketMinute

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Via MarketMinute

Topics Artificial Intelligence Death

3 Mid-Cap Stocks We Steer Clear Of

January 08, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.